Trials / Not Yet Recruiting
Not Yet RecruitingNCT07493174
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
(Limit: 5000 characters) The purpose of this phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory B-cell malignancies, and to provide evidence for recommending a dosage regimen for subsequent studies.
Detailed description
(Limit: 32,000 characters)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYS6055 | The dose will be selected based on the dose cohort, with a single administration. |
Timeline
- Start date
- 2026-04-15
- Primary completion
- 2028-04-15
- Completion
- 2030-04-15
- First posted
- 2026-03-25
- Last updated
- 2026-04-15
Source: ClinicalTrials.gov record NCT07493174. Inclusion in this directory is not an endorsement.